Fiber Formula Study Among Radiation Oncology Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00888147
Recruitment Status : Completed
First Posted : April 27, 2009
Last Update Posted : September 26, 2011
Information provided by (Responsible Party):
Lisa Epp, Mayo Clinic

April 24, 2009
April 27, 2009
September 26, 2011
April 2009
July 2011   (Final data collection date for primary outcome measure)
Whether each patient gets constipated. [ Time Frame: Weekly for 2 weeks ]
Same as current
Complete list of historical versions of study NCT00888147 on Archive Site
Whether the amount of stool softeners/laxatives increases in comparison to the original recommended regimen, for each individual patient. [ Time Frame: Weekly for 2 weeks ]
Same as current
Not Provided
Not Provided
Fiber Formula Study Among Radiation Oncology Patients
Pilot Study: "Does Using a Fiber Containing Enteral Tube Feeding Formula Increase Constipation and the Use of Stool Softeners in Patients Undergoing Radiation Therapy and Have a Percutaneous Endoscopic Gastrostomy (PEG) Placed?"

During radiation treatment for head and neck cancer a large percentage of patients at Mayo Clinic Rochester develop the need for tube feeding to meet nutrition and hydration needs. These patients are usually taking pain medication along with a stool softener or laxative. Currently, when these patients get a feeding tube it is our standard practice to choose a fiber-free enteral tube feeding formula as to not worsen their constipation. Currently, there are no guidelines as to which patients are good candidates for fiber containing enteral tube feeding formulas. The investigators hope this study will help determine if fiber containing enteral tube feeding formulas can be used for patients undergoing radiation for head and neck cancer without increasing rates of constipation or increasing use of stool softeners/laxatives.

Hypothesis: Participants enrolled in the study will not have increased rates of constipation on fiber-containing enteral tube feeding formula compared to historical standards on fiber-free formula.

Not Provided
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
These participants have head and neck cancer, are undergoing radiaiton therapy and will have a percutaneous endoscopic gastrostomy (PEG) placed.
Dietary Supplement: Fiber containing tube feeding formula
This group will be prescribed adequate calories, protein and fluid using a formula that contains fiber.
Other Name: There is no brand name we are using. We will use the formula that best meets the patient calorie, protein and fluid needs.
Fiber formula
This group will receive tube feeding formula that contains fiber.
Intervention: Dietary Supplement: Fiber containing tube feeding formula
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2011
July 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Cancer of: 1) lip/oral cavity 2) pharynx 3) larynx 4) nasal cavity/paranasal sinus 5) salivary gland 6) Thyroid according to AJCC cancer staging manual 6th edition 2002
  • Current radiation therapy or starting radiation therapy in the next 2 weeks
  • Patient must have a gastrostomy tube

Exclusion Criteria:

  • Jejunostomy tube
  • Diagnosis of Irritable Bowel Syndrome (abdominal pain and diarrhea or constipation lasting at least three months in one year)
  • Short bowel (A patient is generally considered to have short bowel syndrome when less than 100 to 150 centimeters of functioning small bowel remains)
  • Body max index (BMI) <18.5kg/m2
  • Gastroparesis (when the stomach retains food for longer than normal periods). This must be diagnosed with a gastric emptying study.
  • Use of Metoclopramide
  • Receiving 5-FU chemotherapy
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Lisa Epp, Mayo Clinic
Mayo Clinic
Not Provided
Principal Investigator: Lisa M Epp, BS Mayo Clinic
Study Director: Yolanda I Garces, MD Mayo Clinic
Mayo Clinic
September 2011